Arunjyoti Bio Ventures Limited returned to profitability in the first quarter of FY27, reporting a net profit of ₹61.24 lakh for the period ended June 30, 2026. This marks a significant recovery from the net loss of ₹204.54 lakh recorded in the corresponding quarter of the previous year. Revenue from operations for the quarter stood at ₹820 lakh, while total income reached ₹822.06 lakh.

The board approved the unaudited financial results and the Limited Review Report for the quarter ended June 30, 2026, at a meeting held on July 9, 2026. The results were reviewed by the Audit Committee and the Statutory Auditors. PKF Sridhar & Santhanam LLP, the Independent Auditor, conducted the limited review in accordance with the Standard on Review Engagement (SRE) 2410.

Financial Performance

The company's total expenses for the quarter were ₹740.22 lakh, a decrease from ₹655.54 lakh in the prior year period. Profit before exceptional items and tax was ₹81.84 lakh, compared to ₹216.91 lakh in Q1FY26. The tax expense for the quarter was ₹20.60 lakh, comprising a current tax of ₹12.44 lakh and a deferred tax charge of ₹8.16 lakh.

Key Financial Metrics

Corporate Governance Updates

In addition to the financial results, the board approved several key governance measures. The company will change its name from “Arunjyoti Bio Ventures Limited” to “Pasura Industries Limited,” subject to shareholder approval. This change necessitates alterations to the Articles of Association and Memorandum of Association.

The board accepted the resignation of M/s. Manoj Parakh & Associates as Secretarial Auditors effective July 9, 2026. Consequently, M/s. Vivek Surana & Associates were appointed as the new Secretarial Auditors to fill the casual vacancy. Their tenure extends until the conclusion of the next Annual General Meeting and for a period of five years, covering financial years 2026-27 to 2030-31, subject to member approval.

Furthermore, the board approved the waiver of recovery of excess managerial remuneration amounting to ₹25.19 lakh paid to Mr. Pabbathi Badhri Narayana Murthy, Whole-time Director, and Mr. Nadimpalli Vishal, Whole-time Director and CFO, for the financial year 2025-26. This waiver is also subject to shareholder approval.

Arunjyoti Bio Ventures Limited held its Board of Directors meeting on 13.05.2026 at its registered office in Madhapur, Hyderabad. The board considered and approved the audited financial results for the quarter and year ended 31 March 2026, along with the Auditor's Report. The board also approved the write-off of outstanding debtors and creditors amounting to Rs. 2,73,64,542/- in the books of accounts of the company. The meeting commenced at 04:15 P.M. and concluded at 05:45 P.M.

Financial Performance: Quarter and Year Ended 31 March 2026

The company's revenue from operations for Q4FY26 stood at ₹723.73 lakhs, compared to ₹646.82 lakhs in Q3FY26 and ₹528.10 lakhs in Q4FY25. For the full year, revenue from operations was ₹2,775.44 lakhs against ₹2,788.41 lakhs in the previous year. The following table summarises the key financial results:

Employee benefit expenses rose sharply to ₹1,123.49 lakhs for FY26 compared to ₹134.72 lakhs in FY25. Finance costs declined to ₹204.73 lakhs in FY26 from ₹893.12 lakhs in FY25. Depreciation and amortisation expenses for FY26 stood at ₹335.81 lakhs versus ₹258.87 lakhs in the prior year.

Exceptional Items

The company recognised exceptional items totalling ₹273.65 lakhs during Q4FY26 and for the full year FY26. These comprised bad debts written off and advances to vendors written off, as detailed below:

Additionally, certain operational bottlenecks and process inefficiencies during Q4FY26 resulted in abnormal consumption of inventory amounting to Rs. 241 lakhs, recognised under consumption of stores and consumables for the quarter and year ended 31 March 2026.

Balance Sheet Highlights

The company's total assets as at 31 March 2026 stood at ₹5,416.29 lakhs, compared to ₹6,138.76 lakhs as at 31 March 2025. Total equity declined to ₹2,871.81 lakhs from ₹3,325.42 lakhs in the prior year. Key balance sheet figures are presented below:

Cash Flow Summary

Net cash generated from operating activities for the year ended 31 March 2026 was ₹1,036.40 lakhs, compared to ₹161.85 lakhs in the previous year. Net cash used in investing activities was ₹484.40 lakhs, while net cash used in financing activities was ₹598.55 lakhs. Cash and cash equivalents at the end of the year stood at ₹12.67 lakhs, down from ₹59.22 lakhs at the beginning of the year.

Prior Period Restatement and Auditor's Report

During the year, the company identified and corrected a prior period error relating to deferred tax on depreciation differences and recognition of previously unavailed tax benefit on unabsorbed depreciation. In accordance with Ind AS 8, comparative figures have been restated; the adjustment is non-cash in nature and has no impact on the company's operating performance or cash flows. The statutory auditors, PKF Sridhar & Santhanam LLP (Firm Registration No. 003990S/S200018), issued an unmodified audit opinion on the standalone audited financial results for the quarter and year ended 31 March 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The auditors drew attention to the restatement of deferred tax computation and the write-off of certain balances amounting to Rs. 273.65 lakhs, though their opinion was not modified in respect of these matters. The declaration of unmodified opinion was submitted by Whole-Time Director P.B.N. Murthy (DIN: 01445523) on behalf of the board.